REDWOOD CITY, Calif., Nov. 15, 2016 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 in New York City.
Nevro management is scheduled to present at 10:00 a.m. ET. The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/Investors.
Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:Nevro Investor RelationsKatherine Bock(650) [email protected]
Advertisement
Nevro management is scheduled to present at 10:00 a.m. ET. The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/Investors.
Advertisement
Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The Senza system is the only SCS system that delivers Nevro's proprietary HF10 therapy. Senza, HF10, Nevro and the Nevro logo are trademarks of Nevro.
Investor Relations Contact:Nevro Investor RelationsKatherine Bock(650) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nevro-to-present-at-the-28th-annual-piper-jaffray-healthcare-conference-300363364.html
SOURCE Nevro Corp.
